[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100388022":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":36,"centralContacts":40,"locations":49,"responsibleParty":67,"collaborators":45,"id":69,"slug":45,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":45,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":45,"enrollmentInfo":77,"targetDuration":45,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":45,"overallStatus":52,"whyStopped":45,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Carboplatin, Taxane And Ramucirumab","EXPERIMENTAL","Carboplatin AUC 5 IV every 3 wks, Paclitaxel 80 mg\u002Fm2 IV days 1 and 8 every 3 weeks, and Ramucirumab 10 mg\u002Fkg IV every 3 weeks",[13,14,15],"Drug: Carboplatin","Drug: Paclitaxel","Drug: Ramucirumab",[17,24,30],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Carboplatin","Carboplatin IV",[9],[23],"Paraplatin",{"type":18,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"Paclitaxel","Paclitaxel IV",[9],[29],"Abraxane, Taxol",{"type":18,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"Ramucirumab","Ramucirumab IV",[9],[35],"Cyramza",[37],{"name":38,"affiliation":5,"role":39},"Melina Marmarelis, MD","PRINCIPAL_INVESTIGATOR",[41,47],{"name":42,"role":43,"phone":44,"phoneExt":45,"email":46},"Melissa Volpe, BA","CONTACT","215-220-9703",null,"Melissa.volpe@pennmedicine.upenn.edu",{"name":38,"role":43,"phone":48,"phoneExt":45,"email":45},"267-438-8154",[50],{"facility":51,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"Abramson Cancer Center of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-75.16362,39.95238,{"lat":62,"lon":61},[65],{"name":66,"role":43,"phone":44,"phoneExt":45,"email":46},"Melissa Volpe",{"type":68,"investigatorFullName":45,"investigatorTitle":45,"investigatorAffiliation":45,"oldNameTitle":45,"oldOrganization":45},"SPONSOR","100388022",false,"NCT04332367","Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance","Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And\u002FOr Pembrolizumab","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to 4-6 cycles of Pem\u002FCarbo\u002FPembro and PD after at least 18 weeks of maintenance Pemetrexed, Pembrolizumab or the combination of the two.\n* PS 0-1\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* Other active invasive malignancy requiring ongoing therapy\n* Grade 2 or higher sensory neuropathy\n* Evidence of untreated brain metastases\n* History of bleeding diatheses or recent, antecedent hemoptysis (\\> 1\u002F2 teaspoon in prior 2 months)","ALL","18 Years",{"count":78,"type":79},59,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.",[85],"Non-small Cell Lung Cancer","2026-06-08",{"date":88,"type":89},"2026-06-10","ACTUAL",{"date":91,"type":89},"2020-08-01",{"date":93,"type":79},"2026-09-30",{"name":5,"class":6},1]